<DOC>
	<DOCNO>NCT01698801</DOCNO>
	<brief_summary>To determine efficacy lenalidomide combination low-dose dexamethasone Japanese subject previously untreated multiple myeloma .</brief_summary>
	<brief_title>A Phase 2 Study Lenalidomide Evaluate Efficacy Japanese Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age ≥ 20 year time signing informed consent document Understand voluntarily sign informed consent document prior study related assessments/procedures conduct Able adhere study visit schedule protocol requirement Previously untreated , symptomatic multiple myeloma Have measurable disease protein electrophoresis analysis At least 65 year age old , young 65 year age , candidate hematopoietic stem cell transplantation Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Must agree comply Lenalidomide Pregnancy Prevention Risk Management Plan Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study Any condition confounds ability interpret data study Previous treatment antimyeloma therapy Pregnant lactating female Any follow laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/microL ( 1.0 × 10^9/L ) Untransfused platelet count ( platelet count drawn least 7 day administration last platelet transfusion ) &lt; 50,000 cells/microL ( 50 × 10^9/L ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3.0 × upper limit normal Renal failure require hemodialysis peritoneal dialysis Prior history malignancy , MM , unless subject free disease ≥ 5 year Subjects unable unwilling undergo antithrombotic therapy . Peripheral neuropathy ≥ grade 2 severity . Uncontrolled systemic fungal , bacterial , viral infection Known human immunodeficiency virus ( HIV ) positivity ( subject receive antiretroviral therapy HIV disease ) Hepatitis Bs ( HBs ) antigenpositive , hepatitis C virus ( HCV ) antibodypositive . In case HBc antibody and/or HBs antibody positive even HBs antigennegative , Hepatitis B virus ( HBV ) DNA test perform positive subject exclude . Primary AL ( immunoglobulin light chain ) amyloidosis myeloma complicate amyloidosis . Ineligible dexamethasone dexamethasone contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>newly diagnose multiple myeloma</keyword>
</DOC>